In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Brian A Ference
Speaker
Brian A Ference
Brian A Ference Brian A Ference

University of Cambridge, Cambridge (United Kingdom of Great Britain & Northern Ireland)

Specialities : Risk Factors and Prevention , Coronary Artery Disease Chronic, Interventional Cardiology, Research Methodology

Brian is a cardiologist and genetic epidemiologist who was educated and trained at Yale, Harvard, Oxford and Cambridge Universities. He is currently Professor / Director of Research in Translational Therapeutics, and Executive Director of the Centre for Naturally Randomized Trials at the University of Cambridge, UK; and Professor of Cardiovascular Medicine at the University of Milan, Italy. His previous posts included Chief of Cardiology at Wayne State University School of Medicine in the US; Chief Medical and Scientific Officer for a public-private collaboration in Beijing; and CEO of a biotechnology company. His research focuses on using Mendelian randomization to design ‘naturally randomized trials’ to generate randomized evidence that can be used to improve the drug discovery and development process; inform the optimal design of randomized trials; fill evidence gaps when a randomized trial is not possible or practical; and define the practice of precision cardiovascular medicine.

22 presentations from this speaker

Effect of BMI and Polygenic Scores on Lifetime Risk of Diabetes

Event : ESC Congress 2020

  • Session : Late-Breaking Science in Diabetes and the Heart
  • Speaker : BA Ference (Cambridge,GB)

Effects of Long-term Exposure to Elevated LDL-C Call for New Treatment Approaches.

Event : ESC Congress 2020

  • Session : Lower for Longer: Reducing Cumulative Exposure to Elevated LDL-C to Prevent Cardiovascular Disease
  • Speaker : BA Ference (Cambridge,GB)
  • Sponsored by Novartis AG

Lifetime Risk of Cardiovascular Disease Based on Cumulative Exposure to Lipoproteins and SBP

Event : ESC Congress 2020

  • Session : Late-Breaking Science in Risk Factors and Prevention
  • Speaker : BA Ference (Cambridge,GB)

Lower for Longer: Reducing Cumulative Exposure to Elevated LDL-C to Prevent Cardiovascular Disease. - Sponsored by Novartis AG

Event : ESC Congress 2020

  • Session : Lower for Longer: Reducing Cumulative Exposure to Elevated LDL-C to Prevent Cardiovascular Disease
  • Speaker : BA Ference (Cambridge,GB), J Kastelein (Amsterdam,NL), A Navar (Durham,US), F J Raal (Johannesburg,ZA)
  • Sponsored by Novartis AG

State-of-the-art lecture - Lifetime risk assessment for cardiovascular disease.

Event : ESC Congress 2020

  • Session : Primary Prevention in Young and Old: the Role of Risk Prediction
  • Speaker : BA Ference (Cambridge,GB)

Combined effect of lower LDL-C and lower SBP on the lifetime risk of cardiovascular disease

Event : ESC Congress 2019

  • Session : Meet the trialist - Combined effect of lower LDL-C and lower SBP on the lifetime risk of cardiovascular disease
  • Speaker : BA Ference (Cambridge,GB)

Cumulative exposure - Estimating the benefits of intervention

Event : ESC Congress 2019

  • Session : Insights and innovation - Can we alter the course of atherosclerotic cardiovascular disease?
  • Speaker : BA Ference (Cambridge,GB)
  • Sponsored by the Medicines Company

Evolution of risk and benefit-based primary prevention in European Guidelines.

Event : ESC Congress 2019

  • Session : Moving from risk to benefit in prevention Guidelines
  • Speaker : BA Ference (Cambridge,GB)
  • Joint with the American Heart Association

LDL-C reducing agents; what genetic tells us

Event : ESC Congress 2019

  • Session : Hypercholesterolemia management - What will be our options after tomorrow?
  • Speaker : BA Ference (Cambridge,GB)
  • Sponsored by Mylan

LDL-c targets in the ESC-EAS dyslipidaemia guidelines in a nutshell

Event : ESC Congress 2019

  • Session : LDL-c guidance on the novel ESC/EAS dyslipidaemia guidelines: expert discussions on practical implications
  • Speaker : BA Ference (Cambridge,GB)
  • Organised by PACE-CME, supported with educational grants provided by Amgen, Pfizer and Sanofi-Regeneron

Risk stratification for atherosclerotic cardiovascular disease.

Event : ESC Congress 2019

  • Session : 2019 ESC/EAS Guidelines on Dyslipidaemias
  • Speaker : BA Ference (Cambridge,GB)

Lp(a): Is there any benefit from reducing it?

Event : ESC Congress 2018

  • Session : Lipid-lowering therapy beyond LDL Cholesterol
  • Speaker : BA Ference (Cambridge,GB)

Mendelian randomization: the future of precision risk estimation?

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2018

  • Session : Risk estimation: Time to re-think?
  • Speaker : BA Ference (Cambridge,GB)

PCSK9 as target for treatment: the genetic validation.

Event : ESC Congress 2018

  • Session : PCSK9 inhibition: science, outcomes and guidance (EBAC Accredited)
  • Speaker : BA Ference (Cambridge,GB)
  • Organised by PACE-CME - Physicians' Academy for Cardiovascular Education, supported with educational grants provided by Amgen and Sanofi-Regeneron

Naturally randomized 'REVEAL' trial

Event : ESC Congress 2017

  • Session : Hot Line: Late-Breaking Clinical Trials 3
  • Speaker : BA Ference (Cambridge,GB)

The LDL-C paradigm.

Event : ESC Congress 2017

  • Session : PCSK9 inhibitors: the evidence-based story
  • Speaker : BA Ference (Cambridge,GB)
  • Sponsored by Amgen GmbH

A naturally randomized trial comparing the effect of long-term exposure to lower LDL-C, lower SBP, or both on the risk of cardiovascular disease .

Event : ESC Congress 2016

  • Session : Meet the Trialist III - A naturally randomized trial comparing the effect of long-term exposure to lower LDL-C, lower SBP, or both on the risk of cardiovascular disease .
  • Speaker : BA Ference (Cambridge,GB)

Panel discussion & Q&A - Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion.

Event : ESC Congress 2015

  • Session : Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion
  • Speaker : C Cannon (Boston,US), U Laufs (Leipzig,DE), BA Ference (Cambridge,GB), AK Gitt (Ludwigshafen,DE), P Toth (Sterling,US)
  • Sponsored by MSD

What mendelian studies can teach: using naturally randomized genetic data to fill evidence gaps.

Event : ESC Congress 2015

  • Session : Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion
  • Speaker : BA Ference (Cambridge,GB)
  • Sponsored by MSD

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are